Lutetium PSMA (Lutetium-177), theranostic medicine and future advances in prostate cancer are coming to an oncology centre near you faster than you can say "novel drug development" and "progression-free survival". This week Michael and Josh conclude their epic prostate cancer trilogy by exploring theranostic medicine and radioactive drug development while looking at the past of the cytotoxic world and the role of cabazitaxel. To ensure we keep your attention, six trials are discussed today, and a shout out to TheraP, the Australian phase 2 trial from the land down under.

Links to studies discussed in this episode (subscription may be required):

Tropic trial: https://www.thelancet.com/article/S0140-6736(10)61389-X/fulltext

CARD trial: https://www.nejm.org/doi/full/10.1056/nejmoa1911206

Corn et al: https://pubmed.ncbi.nlm.nih.gov/31515154/

TheraP: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00237-3/fulltext

Vision: https://www.nejm.org/doi/full/10.1056/nejmoa2107322

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of:

- Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

- SoulProdMusic: https://pixabay.com/users/soulprodmusic-30064790/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.